3. Baseline IgE levels.
Study | IgE level (mean) |
Bardelas 2012 | 180 IU/mL ± 130.5 |
Boulet 1997 | 1152.4 IU/mL (data skewed: SD 2304.5) |
Busse 2001 | 179.26 IU/mL |
Busse 2011 | Unclear |
Chanez 2010 | 220.2 IU/mL ± 151.96 |
Djukanovic 2004 | Median: omalizumab group: 155.5; placebo group: 141 |
Fahy 1997 | 141.5 IU/mL |
Fahy 1999 | 230.1 IU/mL |
Garcia 2012 | Not stated |
Gevaert 2012 | Not stated |
Hanania 2011 | 176.9 IU/mL |
Holgate 2004 | 266.26 IU/mL |
INNOVATE | Between 30 and 1300 IU/mL (no mean given) |
Lanier 2009 | 469.7 IU/mL ± 338.0 |
Massanari 2010 | 176.63 IU/mL ± 138.018 |
Milgrom 1999 | 441.7 IU/mL |
Milgrom 2001 | 339.85 IU/mL |
NCT00096954 | ≥ 30 to ≤ 1300 IU/mL; no mean given |
NCT01007149 | Unclear |
Ohta 2009 | 508.1 IU/mL |
Prieto 2006 | 199.2 IU/mL |
SOLAR | 193.6 IU/mL |
Solèr 2001 | 214.38 IU/mL |
van Rensen 2009 | Unclear |